Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | TK1 | P04183 | 2/20 | 0.58 |
| ▸ | ALB | P02768 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | POLA1 | P09884 | 1/20 | 0.41 |
| ▸ | POLD1 | P28340 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19881438 | 0.87 | LMNA (0.53) | LMNATSHRTK1ALBPKM | |
| SCHEMBL25514132 | 0.82 | TK1 (0.44) | LMNATSHRTK1BLMPMP22 | |
| SCHEMBL21414072 | 0.82 | TK1 (0.44) | LMNATSHRTK1BLMPMP22 | |
| SCHEMBL25914362 | 0.78 | ABCG2 (0.36) | LMNATSHRTK1ALBPKM | |
| SCHEMBL20369178 | 0.78 | LMNA (0.50) | LMNATSHRTK1ALBPKM | |
| SCHEMBL26941474 | 0.78 | LMNA (0.54) | LMNATSHRTK1ALBPKM | |
| SCHEMBL14188556 | 0.77 | TK1 (0.56) | LMNATSHRTK1ALBPKM | |
| SCHEMBL13450792 | 0.77 | TK1 (0.56) | LMNATSHRTK1ALBPKM | |
| SCHEMBL16450527 | 0.74 | TK1 (0.34) | LMNATK1POLB | |
| SCHEMBL24517721 | 0.73 | LMNA (0.39) | LMNATSHRTK1ALBPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11254702-B2 | Thionyl tetrafluoride modified compounds and uses | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-02-22 | — | — | US | disclosed |
| US-20190284226-A1 | THIONYL TETRAFLUORIDE MODIFIED COMPOUNDS AND USES | THE SCRIPPS RESEARCH INSTITUTE | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190284226-A1 | THIONYL TETRAFLUORIDE MODIFIED COMPOUNDS AND USES | SFXN3, TST, SIRT3 | LMNA 3980/4885TSHR 1094/4885TK1 1694/4885 |
| US-11254702-B2 | Thionyl tetrafluoride modified compounds and uses | SFXN3, TST, SIRT3 | LMNA 3980/4885TSHR 1094/4885TK1 1694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.